Domperidon-EP

There is no image.

Domperidone

Method of action: Antiemetic, Drugs For Functional Gastrointestinal Disorders

Treatment option: Pain, Heartburn, Flatulence, Belching, Oral Cavity, Burping, Reflux, Morning Sickness, Esophagitis

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Domperidon-EP

Property	Description
Active Ingredient	Domperidone
Form	Tablet, Oral Suspension, ODT
Pharmacological Class	Dopamine-2 Receptor Antagonist
General Purpose	Counteracts nausea, vomiting, and upper gut motility issues
Origin	Synthetic Organic Compound

What Type of Medicine is Domperidon-EP?

Domperidon-EP is a distinct pharmaceutical product whose sole active ingredient is Domperidone (INN). This compound is classified pharmacologically as a Dopamine-2 receptor antagonist, functionally grouping it as both an antiemetic (to prevent sickness) and a prokinetic agent (to stimulate gastrointestinal movement). The substance itself is defined as a synthetic organic compound, and the product is invariably a single-ingredient product designed to address specific digestive dysfunctions. The preparation is available for oral administration most commonly as a conventional tablet, an orally disintegrating tablet (ODT), or an oral suspension, providing flexibility tailored for different patient demographics.

Domperidone's Focused Mechanism and General Purpose

The general purpose of Domperidon-EP is to counteract the physical symptoms of digestive distress, such as nausea and vomiting, that originate from impaired upper gastrointestinal function. The drug's therapeutic utility is guided by its peripheral selectivity, a property clinically recognized in pharmacological studies, meaning its mechanism of action is primarily concentrated on receptors outside the central nervous system, particularly in the gut and the Chemoreceptor Trigger Zone (CTZ). This targeted action is achieved through dopamine receptor blockade, which suppresses the signals that initiate sickness and simultaneously enhances gastric motility. The resultant gastroprokinetic properties expedite the transit of stomach contents, providing relief from discomforts like abdominal distension and a pronounced epigastric sense of fullness.

Composition and Forms of Domperidon-EP

The foundational composition of Domperidon-EP centers on its active substance, Domperidone (C22H24ClN5O2). Beyond the active drug, the final medicinal entity requires a suitable base or vehicle, which is a solid base for tablets utilizing inert excipients, or a liquid base for the oral suspension using aqueous components, a form often important for pediatric patient groups. While the primary forms are for the oral route of administration, the product has also been prepared as a suppository for rectal administration. This variety in dosage forms ensures the active ingredient is delivered effectively to maximize its antiemetic and prokinetic effects within the upper digestive tract.

What side effects are possible with Domperidon-EP?

Official Safety Profile and Adverse Reactions

The safety profile of Domperidon-EP is defined by official regulatory documents that classify potential adverse reactions by frequency and physiological system. The most significant safety concerns, as documented by authorities like the European Medicines Agency (EMA) and the U.S. FDA, relate to the cardiovascular system, with specific warnings concerning QT prolongation, ventricular arrhythmia, and sudden cardiac death.

Risk assessment notes that the potential for these serious cardiac adverse reactions is higher with longer treatment duration (beyond one week) and at higher daily doses.

Regulatory Classification of Adverse Effects

Adverse reactions are organized into System-Organ Classes (SOCs) and categorized by incidence:

Common (may affect up to 1 in 10 people) reactions include dry mouth.
Uncommon (may affect up to 1 in 100 people) reactions may involve diarrhoea, anxiety, asthenia (weakness), and certain effects on the reproductive system such as galactorrhoea (unusual milk flow).
Not Known (frequency cannot be estimated from available data) reactions include severe events like anaphylactic shock and extrapyramidal disorder (involuntary movements).

Safety Restrictions and Constraints

Official labeling defines strict safety constraints, noting that the medicine is contraindicated in patients with pre-existing QT prolongation, significant electrolyte disturbances (such as low potassium), or underlying cardiac diseases (such as congestive heart failure). Use is also prohibited in cases of severe hepatic impairment and with concomitant use of powerful inhibitors of the CYP3A4 enzyme or other medicines known to prolong the QT interval.

Overdose and Emergency Response

Overdose and when to seek help

Documented Overdose Manifestations

Official regulatory documentation identifies overdose presentations that center on CNS depression and movement disorders. Manifestations listed include somnolence (drowsiness), disorientation (confusion), and extrapyramidal symptoms. These movement issues may include unusual movements of the tongue, irregular eye movements, and abnormal posture.

Serious Outcomes and Risk Factors

Overdose carries risks to the Cardiovascular system, with documented concerns for QTc prolongation, ventricular arrhythmias, and the potential for sudden cardiac death. A severe neurological outcome documented is convulsion (seizure).

Risk is specifically noted as higher in patients older than 60 years and those exposed to doses greater than 30 mg daily. Extrapyramidal symptoms are documented as more likely to happen in children in overdose scenarios.

Regulator-Mandated Emergency Actions

Regulators mandate that patients seek medical attention straight away for any suspected overdose. It is required to go to a hospital straightaway if signs such as uncontrolled movements, a very fast or unusual heartbeat, or a fit (seizure) are noticed. Management involves standard symptomatic and supportive treatment; ECG monitoring should be undertaken due to the possibility of QTc interval prolongation.

Connection to the Overall Overdose Profile

Regulatory documents define the overdose profile by its potential for life-threatening cardiovascular events and neurological manifestations. This framing strictly dictates that immediate medical attention must be sought for specific severe signs, requiring hospital monitoring and symptomatic support.

Therapeutic Uses of Domperidon-EP

Domperidon-EP may be part of symptomatic management, applied across domains involving increased discomfort or tension related to upper gastrointestinal function.

What Domperidon-EP Helps Manage: Symptoms and Benefits

The medication is considered relevant for easing symptoms linked to organ-specific functional stress, applicable within the domain of functional motility impairment. It helps address symptom clusters that include uncomfortable post-meal fullness, early satiety, abdominal distension, and general epigastric discomfort. In conditions like gastroparesis, it supports functional stability and assists with maintaining day-to-day comfort, which may help patients cope more steadily with symptom fluctuations.

It is commonly used to help with the acute feelings of nausea and episodes of vomiting. It helps with managing these symptoms when they appear suddenly or become disruptive, such as in cases where sickness is linked to upper digestive issues or is a secondary manifestation of certain necessary pharmacological treatments, like those used for Parkinson’s disease.

It is considered relevant for easing the overall symptom load and may contribute to improved comfort during periods of heightened symptoms.

The primary symptom axes for which the medication is applied include nausea, vomiting, post-meal fullness, and early satiety. Additionally, it is relevant for use in specialized scenarios, including supportive management in palliative care and lactation support for breastfeeding mothers. This is applied in settings where supportive symptom management is appropriate.

Quick Fact: Relief for Post-meal Fullness and Nausea

Eligibility and Restrictions for Use

Eligibility Map: Official Regulatory Information

Populations for whom use is allowed (as stated in label):

Adults (18 years and older).
Adolescents 12 years of age or older and weighing 35 kg or more.

Populations for whom use is contraindicated:

Patients with moderate or severe hepatic impairment (liver failure).
Patients with known cardiac conduction intervals prolongation (e.g., QTc), underlying cardiac diseases (e.g., congestive heart failure), or significant electrolyte disturbances (e.g., hypokalaemia).
Patients with a prolactin-releasing pituitary tumour (prolactinoma).
Patients with gastrointestinal haemorrhage, mechanical obstruction, or perforation where stimulating gut motility could be harmful.
Patients taking specific QT-prolonging medicines or potent CYP3A4 inhibitors.

Age-related eligibility rules:

Use is generally not recommended or no longer licensed for children younger than 12 years of age or those weighing less than 35 kg.
Use in patients older than 60 years requires caution, as a higher risk of serious ventricular arrhythmias has been observed in this age group.

Condition-specific eligibility rules:

Severe renal impairment is not a contraindication but requires a reduction in administration frequency due to prolonged drug elimination.

Pregnancy and lactation eligibility status (if explicitly documented):

Pregnancy: Should only be used if the anticipated benefit outweighs the potential risk.
Lactation: Requires a careful risk/benefit assessment as the drug is excreted in human milk.

Connection to the overall eligibility profile: Regulatory documents establish that eligibility is primarily defined by absolute contraindications targeting cardiac safety and organ function integrity, particularly the liver. These restrictions delineate a narrow authorized population, ensuring exclusion of groups where regulatory review indicates a heightened risk or a lack of established efficacy.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Domperidon-EP’s interaction profile is structured around metabolic inhibition and additive cardiac risk, leading to formal usage prohibitions documented by regulatory authorities.

Official Regulatory Interaction Constraints

Interaction Type	Interacting Product Category	Regulatory Restriction
Pharmacokinetic (Exposure)	Potent CYP3A4 Inhibitors (e.g., Ketoconazole, Erythromycin)	Formal Contraindication: Prohibited due to reduced clearance and a multi-fold increase in Domperidone plasma concentrations.
Pharmacodynamic (Cardiac)	Medicines that Prolong the QTc Interval (e.g., Amiodarone, Haloperidol)	Formal Contraindication: Prohibited due to the risk of an additive effect on cardiac repolarization, increasing the risk of serious ventricular arrhythmias.

Mechanism of Action

Blocking Peripheral Dopamine Signals

This mechanism centers on the drug's role as an antagonist (blocker) of Dopamine D2 and D3 receptors primarily located outside the main brain structure, in the Chemoreceptor Trigger Zone (CTZ) and the gastrointestinal (GI) tract wall. The drug's antagonism in the CTZ modifies the activation of the signal pathway that influences the emetic center.

Enhancing Upper Digestive Tract Movement

The drug's targeted action within the gastrointestinal motility pathway involves blocking inhibitory dopamine receptors on the smooth muscles of the stomach and the lower esophagus. This removal of the inhibitory influence allows the inherent pro-motility signals to increase the strength of contractions, resulting in an accelerated rate of gastric emptying.

Modulating Neuroendocrine Hormone Release

The mechanism also includes interaction with the hypothalamic-pituitary axis, where D2 receptor blockade occurs in the anterior pituitary gland. The D2 receptor blockade removes the natural inhibition of prolactin release, resulting in an elevated concentration of prolactin in the circulation.

Dosage and Administration Information

How to use Domperidon-EP — Administration Guidelines

Domperidon-EP must be used at the lowest effective dose for the shortest duration necessary, which should not typically exceed one week to manage the symptoms of nausea and vomiting.

Administration and Dosing

Route of Administration: Oral (tablets, orodispersible tablets, or oral suspension) is the primary route. Rectal administration via a 30 mg suppository twice daily is an alternative route in adults where approved.

Timing and Frequency: Oral formulations are recommended to be taken before meals/feeding (e.g., 15 to 30 minutes before) as absorption is delayed when taken after food. Doses should be spaced by at least 4 to 6 hours and taken up to three times per day.

Patient Group (Weight)	Recommended Dose per Intake	Maximum Daily Dose
Adults & Adolescents (≥ 12 years and ≥ 35 kg)	10 mg (Tablet or 10 ml Suspension)	30 mg (30 ml Suspension)
Children & Adolescents (< 35 kg)	0.25 mg/kg (Oral Suspension only)	0.75 mg/kg

Preparation Steps:

Oral Suspension: The liquid must be measured accurately using a suitable oral syringe or dosing device, especially for weight-based pediatric dosing.
Orodispersible Tablets: These tablets dissolve rapidly on the tongue and can be swallowed with or without water.

Missed Dose Instructions: If a dose is missed, it should be omitted, and the usual dosing schedule should be resumed. The dose must never be doubled to compensate for a missed dose.

Special Conditions (Severe Renal Impairment): Patients with severe renal impairment should have their dosing frequency reduced to once or twice daily, and the dose may require reduction to account for prolonged elimination half-life.

Recent Clinical Evidence

Research evidence / Overview of studies

Overview of Clinical Research

Research has explored a novel combination therapy. Research evaluated whether this combination therapy had an effect on the condition.

The combination treatment has been the subject of a comprehensive clinical research program, progressing through Phase I, II, and III trials. The studies examined the treatment's effect on various clinical endpoints, including inflammatory markers, disease activity scores, and quality of life measures.

Phase I: Pharmacokinetics

Initial phase I trial findings reported observations on participant tolerability at the planned therapeutic dose. The trial's primary objective was to define the pharmacokinetics and maximum tolerated dose.

Phase II: Endpoint Exploration

Phase II studies examined whether there were changes in the predefined clinical endpoints. These endpoints included:

Disease Activity Score (DAS) changes
Measures of physical function and pain
Changes in specific inflammatory biomarkers

Research reported changes in inflammation markers in participants receiving treatment at 4 weeks. Studies explored whether the combination affected pain and physical function. The clinical relevance of these findings for managing condition X is still under investigation.

Phase III: Long-Term Outcomes and Comparative Research

The pivotal Phase III trials evaluated the combination therapy in a larger patient population over a longer duration (12 months). The primary outcome was measured by a composite index of disease severity.

Outcomes measured during the studies included a detailed analysis of adverse events and measures of long-term disease control.

The Phase III program evaluated the treatment's effect on long-term disease progression. Results indicated an observable difference compared to placebo.

One study compared outcomes to standard care in reducing relapse rates. The findings require further confirmation. The research evaluated whether there was a change in the frequency of flare-ups.

The trial excluded participants who were taking certain prescription drugs concurrently. Interactions with other treatments have not been fully studied.

Frequently Asked Questions (FAQ)

Common questions about Domperidon-EP (FAQ)

Q: How long does the effect of one Domperidon-EP dose typically last?

Information derived from pharmacokinetic studies, which examine how the body processes the medicine, indicates that the substance typically has a plasma half-life of around 7 to 9 hours in healthy subjects. This means it takes about that long for half of the medicine to be cleared from the bloodstream. However, the elimination time can be longer for individuals with severe kidney problems.

Q: Can Domperidon-EP be taken if someone is also using acid reflux medicine?

Official regulatory documents note that acid reflux medicines, or antisecretory drugs, can reduce how much Domperidon-EP the body absorbs. To help minimize this potential interaction, Domperidon-EP tablets are recommended to be taken before meals, while it is noted that antacids or antisecretory agents are generally administered after meals.

Q: Does Domperidon-EP help with bloating?

Domperidon-EP is used to manage symptoms of indigestion. Because the medicine works as a prokinetic agent to help move food faster through the stomach, it can provide relief from feelings associated with upper digestive distress, such as abdominal distension and a pronounced sense of fullness, which are related to bloating.

Q: Is Domperidon-EP known to cause dry mouth?

Yes, regulatory documents classify dry mouth as a Common adverse reaction. This means that among patients who use Domperidon-EP, dry mouth may affect up to 1 in every 10 people.

Q: Is there any research on Domperidon-EP use during pregnancy?

Official regulatory documents state that the medicine should only be used during pregnancy if the potential benefit is judged to outweigh the potential risk. Given this caution, it is noted by some authoritative sources that alternative medicines with more established safety profiles are generally preferred.

Q: Are there special warnings about Domperidon-EP for people with existing heart conditions?

Yes. Regulatory labeling states that Domperidon-EP is contraindicated, meaning it must not be used, in patients who have pre-existing conditions that affect the heart. This includes known issues such as cardiac conduction problems (like QT prolongation), underlying heart diseases, or significant disturbances in electrolyte levels.

Q: Is Domperidon-EP safe for older adults to use?

Official regulatory information states that the use of Domperidon-EP in patients older than 60 years requires caution. Regulatory reviews have observed that there is a higher potential for serious heart rhythm disturbances, called ventricular arrhythmias, in this older age group.

Q: Can Domperidon-EP be given to children?

The use of Domperidon-EP is generally restricted to adolescents who are 12 years of age or older and weigh 35 kg or more. Official regulatory bodies have removed the indication for use in children under 12 years due to a less favorable overall benefit-to-risk profile.

Q: Can Domperidon-EP interact with alcohol?

Official guidance indicates that alcohol should ideally be avoided while taking Domperidon-EP. This is because consuming alcohol may potentially intensify some of the drug's side effects, such as increasing the potential for drowsiness or irregular heartbeat.

Q: Is there official guidance on discontinuing Domperidon-EP use?

Regulatory instructions mandate that the maximum duration of treatment should not typically exceed one week. Additionally, some post-marketing safety reports have noted cases of psychiatric withdrawal events upon sudden discontinuation, particularly when the drug was used off-label at higher doses.

Q: Is Domperidon-EP considered a common treatment for nausea?

Domperidon-EP is a medicine classified as a dopamine antagonist and an anti-sickness medicine (antiemetic). Due to specific safety concerns, some regulatory bodies have moved to reclassify it as a prescription-only medicine, which limits its general availability and use compared to other over-the-counter options.

Q: Is Domperidon-EP the same kind of drug as metoclopramide?

Domperidon-EP and metoclopramide are both classified as anti-sickness medicines (antiemetics). Regulatory notes indicate that Domperidon-EP's action is more targeted outside the main brain structure, suggesting it has a lower likelihood of causing certain central nervous system side effects compared to metoclopramide.

Q: Can Domperidon-EP cause headaches or dizziness?

Yes, some official product information lists headache as a common side effect of Domperidon-EP. Dizziness is also noted as a potential side effect.

Q: Is it normal to feel a bit drowsy after taking Domperidon-EP?

Regulatory information lists drowsiness (sleepiness) as a possible side effect. The labeling notes that caution is advised if side effects are experienced.

Q: Can Domperidon-EP affect blood sugar levels?

Research has investigated the use of Domperidon-EP in patients with diabetic gastropathy, where the drug's effect is focused on improving stomach emptying. This mechanism may indirectly support better control of symptoms related to diabetes, but no direct effect on blood sugar levels is explicitly stated in the regulatory documents.

Q: Have there been recent studies about the long-term use of Domperidon-EP?

The standard duration of treatment is typically restricted to one week or less. However, some clinical research has explored the long-term use (up to 12 years) of Domperidon-EP in highly specific study populations, such as those with diabetic gastropathy, where efficacy and tolerability were reported to be maintained.

Q: Is Domperidon-EP considered a treatment that is supported by clinical evidence?

Regulatory documents and clinical research evidence indicates that Domperidon-EP has shown efficacy in the management of nausea and vomiting symptoms associated with specific conditions like diabetic gastropathy.

Q: Are there specific symptoms that mean someone should stop taking Domperidon-EP?

Official guidance states that treatment should be immediately stopped and medical attention should be sought if signs or symptoms associated with a cardiac arrhythmia (an abnormal heart rhythm or heartbeat) are experienced.

Q: What is the role of Domperidon-EP in treating nausea after chemotherapy?

Domperidon-EP has been reported in literature as effective for treating nausea and vomiting that is associated with chemotherapy (CINV). It has been reported as used in specialized medical settings as an add-on therapy for cases that are difficult to manage.

Q: Are there any known interactions between Domperidon-EP and herbal supplements?

Official sources caution that there is not enough specific information to confirm that other complementary medicines and herbal remedies are safe to take with Domperidon-EP. They may potentially worsen side effects, and it is generally recommended that patients inform their healthcare professional of all concomitant treatments.

Q: Does Domperidon-EP affect mental clarity or focus?

While not listed as a primary side effect, a regulatory safety review noted that the sudden discontinuation of Domperidon-EP (especially at high, off-label doses) has been linked to psychiatric withdrawal events. These events include anxiety and insomnia, which could indirectly impact mental focus and clarity.

Q: Is it possible for Domperidon-EP to cause difficulty sleeping?

A regulatory safety review noted that insomnia (difficulty sleeping) has been reported in some patients as part of a post-discontinuation syndrome. This was primarily observed when the drug was used off-label at higher-than-recommended doses.

Q: How does Domperidon-EP compare to other drugs used to increase gut motility?

Domperidon-EP is classified as a prokinetic agent that helps increase gut movement. Regulatory notes indicate that Domperidon-EP has been compared to other prokinetic drugs, such as metoclopramide, and is cited as demonstrating a lower likelihood of central nervous system side effects compared to metoclopramide.

Q: What is the main difference in how Domperidon-EP and ondansetron work?

Domperidon-EP is classified as a dopamine antagonist that primarily works by blocking D2/D3 receptors. Another antiemetic, such as ondansetron, belongs to a different pharmacological class, specifically as a 5-HT3 receptor antagonist. These different classifications mean the medicines work on different chemical pathways in the body.

Q: Do people report feeling more energetic or less energetic on Domperidon-EP?

Regulatory documents list asthenia (meaning weakness or a lack of energy) as an Uncommon adverse reaction. This means that feeling less energetic may affect up to 1 in 100 people using the medicine.

Q: Can Domperidon-EP affect fertility?

The medicine's mechanism involves interaction with the hypothalamic-pituitary axis, which can lead to increased prolactin levels. Side effects related to the reproductive system, such as galactorrhoea (unusual milk flow), have been reported, but specific effects on fertility are not explicitly detailed in the adverse reaction profiles.

Q: Is Domperidon-EP known to cause changes in mood?

Yes. Anxiety is listed in regulatory documents as an Uncommon adverse reaction. Furthermore, a safety review noted that psychiatric withdrawal events, including depression and anxiety, have been reported following discontinuation of the medicine.

Q: Do any official drug labels mention fatigue as a side effect of Domperidon-EP?

Official labeling lists asthenia (a medical term for weakness or lack of energy) as an Uncommon side effect. This condition is often used interchangeably with fatigue in non-technical and clinical settings.

Q: Is it okay to drive after taking Domperidon-EP?

Official guidance indicates that operating a vehicle or machinery is not recommended if Domperidon-EP causes certain side effects. This specifically includes if the medicine makes the user sleepy or if it causes an irregular heartbeat.

Q: Can Domperidon-EP be taken at the same time as cold or flu medicines?

Official sources caution that Domperidon-EP can interact with a wide range of medicines, including certain antibiotics and heart medicines, which may be components of, or interact with, cold/flu treatments. Users are advised to tell their healthcare professional about all concomitant medicines.

Q: What is the typical timeframe for a doctor to review treatment with Domperidon-EP?

Regulatory instructions mandate that the treatment duration should not typically exceed one week due to safety considerations. Specialized clinical protocols for certain conditions may require a formal physician review after 7 days of treatment.

Q: How is Domperidon-EP related to conditions like Gastroparesis?

Domperidon-EP is a prokinetic agent that stimulates gastric movement. Due to this mechanism, it is commonly used in the specialized management of conditions like Gastroparesis (delayed stomach emptying), although its formal use has been restricted by some regulatory bodies.

How should Domperidon-EP be stored and disposed of?

How to Store and Dispose of Domperidone

Official regulatory guidelines mandate specific conditions for storing Domperidone to maintain its stability and effectiveness. The medicine must be stored at a temperature below 30°C and should be kept in a cool, dry place. It is required to protect the product from light and it must be strictly kept from freezing.

Packaging and Child Safety

Tablets must remain in the original container and be stored in a closed container. A critical requirement is to keep Domperidone out of the sight and reach of children.

Disposal Requirements

Expired or unused Domperidone must not be thrown away via wastewater or household waste. The official instruction is to return the unwanted medicine to a pharmacy for safe disposal according to local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.